4//SEC Filing
Kaufman Jonathan H 4
Accession 0001753926-25-000101
CIK 0001347242other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 8:13 PM ET
Size
12.5 KB
Accession
0001753926-25-000101
Insider Transaction Report
Form 4
Kaufman Jonathan H
DirectorSee remarks below.10% Owner
Transactions
- Other
Series C Voting Convertible Preferred Stock
2025-01-15−303,041→ 0 total(indirect: By Self as proxy and power of attorney for Spartan and an Affiliate (each as defined below))Exercise: $1.00From: 2025-01-15→ Common Stock (303,041 underlying) - Other
Common Stock Purchase Warrants
2025-01-15−85,421→ 0 total(indirect: By Self as proxy and power of attorney for Spartan)Exercise: $1.00From: 2024-12-27Exp: 2029-12-27→ Common Stock (85,421 underlying) - Other
Common Stock Purchase Warrants
2025-01-15−11,795→ 0 total(indirect: By Self as proxy and power of attorney for Spartan)Exercise: $1.00From: 2024-12-31Exp: 2029-12-31→ Common Stock (11,795 underlying)
Footnotes (3)
- [F1]Such Series C Voting Convertible Preferred Stock, par value $0.0001 per share ("Preferred Stock"), and the common stock, par value $0.0001 per share, of the issuer ("Common Stock"), issuable upon conversion of Preferred Stock ("Conversion Shares") and exercise of the Common Stock purchase warrants (the "Warrant Shares", and collectively with the Preferred Stock and Conversion Shares, "Securities") were subject to an irrevocable proxy and power of attorney, effective December 20, 2024, between the reporting person and Spartan Capital Securities, LLC ("Spartan"), pursuant to which the reporting person had voting power over all Securities held by Spartan and its Affiliates (defined under Rule 405 of the Securities Act of 1933, as amended) or any person or entity acting as a group therewith ("Proxy and POA").
- [F2]Upon the effectiveness of a registration statement registering the Securities as of January 15, 2025, such voting power granted to the reporting person by Spartan and such Affiliates was terminated. Please see the Proxy and POA attached as Exhibit 24 to the Form 4 filed by the reporting person with the U.S. Securities and Exchange Commission on January 3, 2025.
- [F3]The conversion rights of the Preferred Stock do not expire.
Documents
Issuer
LIPELLA PHARMACEUTICALS INC.
CIK 0001347242
Entity typeother
Related Parties
1- filerCIK 0001959250
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 8:13 PM ET
- Size
- 12.5 KB